Trust Investment Advisors decreased its stake in shares of Eli Lilly And Co (NYSE:LLY) by 1.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,535 shares of the company’s stock after selling 400 shares during the period. Eli Lilly And Co accounts for 3.8% of Trust Investment Advisors’ investment portfolio, making the stock its 3rd biggest position. Trust Investment Advisors’ holdings in Eli Lilly And Co were worth $3,184,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in LLY. Athena Capital Advisors LLC purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at $26,000. Wakefield Asset Management LLLP purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at $27,000. Larson Financial Group LLC purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at $29,000. Trust Department MB Financial Bank N A grew its position in shares of Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares during the period. Finally, Acima Private Wealth LLC purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at $33,000. 80.69% of the stock is owned by institutional investors.
In related news, SVP Christi Shaw sold 7,577 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $117.14, for a total value of $887,569.78. Following the completion of the transaction, the senior vice president now directly owns 500 shares of the company’s stock, valued at approximately $58,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Insiders sold a total of 640,959 shares of company stock valued at $81,539,352 over the last three months. Corporate insiders own 0.11% of the company’s stock.
A number of brokerages have recently commented on LLY. Barclays reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a report on Wednesday, April 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $143.00 target price on shares of Eli Lilly And Co in a report on Tuesday, April 30th. BMO Capital Markets lowered their target price on Eli Lilly And Co to $130.00 and set an “outperform” rating for the company in a report on Monday, April 22nd. Finally, Bank of America set a $129.00 target price on Eli Lilly And Co and gave the company a “hold” rating in a report on Thursday, March 21st. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $118.15.
LLY stock traded down $1.27 on Thursday, reaching $116.71. The company’s stock had a trading volume of 686,576 shares, compared to its average volume of 4,293,033. Eli Lilly And Co has a 52 week low of $81.61 and a 52 week high of $132.13. The firm has a market capitalization of $113.18 billion, a price-to-earnings ratio of 21.03, a price-to-earnings-growth ratio of 2.07 and a beta of 0.27. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. During the same period in the prior year, the company posted $1.31 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Friday, May 17th will be issued a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a yield of 2.21%. The ex-dividend date of this dividend is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.
COPYRIGHT VIOLATION NOTICE: “Trust Investment Advisors Reduces Holdings in Eli Lilly And Co (LLY)” was first reported by Highlight Press and is owned by of Highlight Press. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://highlightpress.com/2019/05/23/trust-investment-advisors-reduces-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.